Novo Nordisk just locked up global rights to UBT251—everywhere except Greater China. The deal could reach $2 billion. This is not just about filling the pipeline. Novo is fighting to keep its top spot in obesity drugs. Patent expirations are coming. Eli Lilly is closing in.
Novo Nordisk has publicly positioned UBT251 as a next-generation incretin therapy with activity on GLP-1, GIP, and glucagon receptors, aiming for enhanced weight loss and liver benefits.
UBT251 works on GLP-1, GIP, and glucagon receptors at the same time. Adding the glucagon pathway is meant to boost energy use and improve fat metabolism. The goal: better weight loss and heart health. In the same 24-week trial, patients saw mean HbA1c drop by up to 2.16 percent. That’s a strong metabolic effect.
This goes beyond trial results. Novo Nordisk signed the licensing deal with The United Laboratories International in early 2025. The move kept UBT251 away from Eli Lilly and gave Novo a new asset for the next decade. Novo wants to develop UBT251 as both an injectable and a daily pill. That would reach more patients.
In Novo Nordisk's 2026 Capital Markets Day materials, UBT251 is not only positioned as an obesity asset but also as a candidate for MASH (metabolic dysfunction-associated steatohepatitis), with anti-steatotic and antifibrotic potential. The company plans to launch the MASH program for UBT251 in 2027, expanding the asset's scope beyond obesity.
But strong Phase 2 data is only the start. UBT251 still faces Phase 3 trials and must win over the US Food and Drug Administration and European Medicines Agency. Safety is a big question, especially around the glucagon receptor’s effect on liver enzymes and heart health. The market is crowded. Other triple-agonists and oral drugs are close to approval.
Manufacturing brings more risk. Making a peptide that hits three targets needs special bioreactors. Novo Nordisk has already spent billions to expand its plants. If UBT251 clears Phase 3, the company must avoid the supply shortages that have hit GLP-1 drugs.
There’s a bigger shift here. Western pharma used to see Chinese biotechs as suppliers or sources of early compounds. That’s changed. China’s sector now creates first-in-class drugs and runs fast, large trials. The strong Phase 2 data for UBT251 proves it. Global regulators are watching.
Licensing deals are changing the game. As shown in recent transactions, companies are scrambling to grab assets that can move market share and revenue fast.
Novo Nordisk’s bet on Chinese clinical innovation is a clear break from old R&D boundaries. The company’s future in obesity drugs now depends on whether UBT251 can become a safe, scalable, and widely available therapy. Hundreds of millions are waiting. The pressure is on. Every step will be watched.
